1 Department of Gynaecology and Obstetrics, Fifth Hospital of Xi'an, Xi'an, China.
2 Department of Oncology, Affiliated Hospital of Yan'an University, Yan'an, Yan'an, China.
Cancer Biother Radiopharm. 2019 Feb;34(1):47-55. doi: 10.1089/cbr.2018.2565. Epub 2019 Jan 2.
Long non-coding RNA-ATB (Lnc-ATB) have been reported to promote tumor proliferation and metastasis via regulation of tumor suppressive miRNA-related signals. Patients with endometrial cancer (EC) have advanced stage disease or metastasis have poor prognosis. We here investigated the role of Lnc-ATB in endometrial cancer.
Endometrial cancer tissues and normal tissues (n = 35) were collected to determine the expression and clinical significance of Lnc-ATB, and bioinformatics analysis was used to predict the miRNA target. siRNA was used to estimate the function of Lnc-ATB in EC cell lines and in vivo.
The expression of Lnc-ATB is up-regulated in tumor tissues and EC cell lines. Patients with high expressed Lnc-ATB have high FIGO stage and poor tumor differentiation. The tumor suppressor miR-126 interacted with Lnc-ATB. Down-regulated miR-126 negative correlated with FIGO stage and tumor differentiation. Knockdown of Lnc-ATB in RL95 and HEC1A cell lines increased the miR-126 level and impaired the cell vitality, induced caspase-3-related tumor apoptosis and G1/S arrest. However, abrogation of miR-126 by its inhibitors counteracted Lnc-ATB knockdown-induced tumor inhibition via regulation of miR-126 target gene PIK3R2 and Sox2-related apoptosis and cell cycle pathway. Meanwhile, Lnc-ATB knockdown also suppressed the migration and invasion and inhibited TGF-β-induced epithelial-mesenchymal transition (EMT) phenotype via miR-126. Knockdown of Lnc-ATB in vivo remarkably induced tumor regression via restoration of tumor suppressor miR-126, leading to deceased tumor volume, reduced expression of PCNA and PIK3R2/Sox2 signals and EMT phenotype in tumor tissues.
These data demonstrate the tumorigenic role of Lnc-ATBs in endometrial cancer via abrogation of tumor suppressor miR-126 signals.
长链非编码 RNA-ATB(Lnc-ATB)已被报道通过调节肿瘤抑制性 miRNA 相关信号促进肿瘤增殖和转移。患有子宫内膜癌(EC)的患者疾病处于晚期或发生转移,其预后较差。我们在此研究了 Lnc-ATB 在子宫内膜癌中的作用。
收集子宫内膜癌组织和正常组织(n=35),以确定 Lnc-ATB 的表达和临床意义,并进行生物信息学分析以预测 miRNA 靶标。使用 siRNA 估计 Lnc-ATB 在 EC 细胞系和体内的功能。
Lnc-ATB 在肿瘤组织和 EC 细胞系中表达上调。表达水平高的 Lnc-ATB 的患者具有较高的 FIGO 分期和较差的肿瘤分化。肿瘤抑制因子 miR-126 与 Lnc-ATB 相互作用。下调的 miR-126 与 FIGO 分期和肿瘤分化呈负相关。在 RL95 和 HEC1A 细胞系中敲低 Lnc-ATB 会增加 miR-126 水平并诱导 caspase-3 相关的肿瘤凋亡和 G1/S 期阻滞。然而,通过其抑制剂消除 miR-126 会通过调节 miR-126 靶基因 PIK3R2 和 Sox2 相关的凋亡和细胞周期途径来抵消 Lnc-ATB 敲低诱导的肿瘤抑制作用。同时,Lnc-ATB 敲低还通过 miR-126 抑制 TGF-β诱导的上皮间质转化(EMT)表型来抑制迁移和侵袭。体内敲低 Lnc-ATB 通过恢复肿瘤抑制 miR-126,显著诱导肿瘤消退,导致肿瘤体积减小、肿瘤组织中 PCNA 和 PIK3R2/Sox2 信号表达降低以及 EMT 表型减少。
这些数据表明,Lnc-ATB 通过消除肿瘤抑制性 miR-126 信号在子宫内膜癌中发挥致癌作用。